Alendronate gastric ulcers

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 4, 1999, Pages 515-519

  Graham, D Y ^a   Malaty, H M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; ESOPHAGUS INJURY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH INJURY; STOMACH PAIN; STOMACH ULCER; TASTE DISORDER; VERTIGO;

ADULT; ALENDRONATE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESOPHAGUS; FEMALE; GASTRIC MUCOSA; HUMANS; MALE; MIDDLE AGED; STOMACH ULCER;

EID: 0032891749     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00488.x     Document Type: Article

References (34)

1. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81: 961-7.
2. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995; 90: 1889-90.
3. Francis RM. Oral bisphosphonates in the treatment of osteoporosis: A review. Curr Ther Res 1995; 56: 831-51.
4. Gertz BJ, Holland SD, Kline WF, el al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58: 288-98.
5. Braga V, Dorizzi R, Brocco G, et al. Clinical utility of a wheat-germ precipitation assay for determination of bone alkaline phosphatase concentrations in patients with different metabolic bone diseases. Eur J Clin Chem Clin Biochem 1995; 33: 433-9.
6. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320-2.
7. Abdelmalek MF, Douglas DD. Alendronate-induced ulcerative esophagitis. Am J Gastroenterol 1996; 91: 1282-3(Letter).
8. Blank MA, Ems BL, Gibson GW, Myers WL, Phipps RJ, Smith PN. A preclinical model for assessing gastric effects of bisphosphonates (BPs). Gut 1995: 37(Suppl. 2): A206(Abstract).
9. Blank MA, Ems BL, Gibson GW, Myers WL, Phipps RJ, Smith PN. In a novel preclinical model, primary amino bisphosphonates show a greater potential for gastric effects than a pyridinyl bisphosphonate. J Bone Mineral Res 1995; 10: S454(Abstract).
10. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1994; 15: 415-17.
11. Freedholm D, Emkey R, Cummings DC, et al. Safety and tolerabiltty of oral alendronate in the treatment of posmenopausal osteoporosis. Osteoporos Int 1996; (Suppl. 1): 261(Abstract).
12. Liberman UA, Weiss SR, Broll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 1995; 333: 1437-43.
13. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21.
14. Rimmer DE, Rawls DE. Improper alendronate administration and a case of pill esophagitis. Am J Gastroenterol 1996; 91: 2648-9(Letter).
15. Naylor G, Davies MH. Oesophageal stricture associated with alendronic acid. Lancet 1996; 348: 1030-1(Letter).
16. Liberman UI, Hirsch LJ. Esophagitis and alendronate. N Engl J Med 1996; 335: 1069-70(Letter).
17. Castell DO. 'Pill esophagitis' - The case of alendronate. N Engl J Med 1996; 335: 1058-9(Editorial).
18. Pizzani E, Valenzuela G. Esophagitis associated with alendronate sodium. Va Med Q 1997; 124: 181-2.
19. Girelli CM, Reguzzoni G, Rocca F. Alendronate-induced esophagitis. A report of 2 cases. Recenti Prog Med 1997; 88: 223-5.
20. Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997; 102: 489-91.
21. Colina RE, Smith M, Kikendall JW, Wong RK. A new probable increasing cause of esophageal ulceration: Alendronate. Am J Gastroenterol 1997; 92: 704-6.
22. Kelly R, Tuggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. Br Med J 1997; 315: 1235(Letter).
23. Ettinger B, Presman A, Schein J. Chan J, Connolly N. Survey of women taking alendronate: Prevalence of non-compliance with instructions and discontinuation. Osteoporos Int 1997; 7(Suppl. 2): 46(Abstract).
24. Anonymous, Postmarketing surveillance indicates need for better education of patients taking alendronate. Am J Health Syst Pharm 1996; 53: 986(News).
25. Anonymous. Warning about oesophagitis with Fosamax. Lancet 1996; 347: 959(News).
26. Lilley LL, Guanci R. Avoiding alendronate-related esophageal irritation. Am J Nurs 1997; 97: 12-4.
27. Lanza FL, Evans DG, Graham DY. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol 1991; 86: 735-7.
28. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 1990; 35: 1494-9.
29. Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: A new class of gastrotoxic drugs - Comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92: 1322-5.
30. Lanza F, Rack MF, Simon TJ, Lombardi A, Reyes R, Suryawanshi S. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998; 93: 753-7.
31. Lanza F, Rack MF, Simon T, Lombardi A, Reves R, Suryawashi S, Effects of alendronate on gastric and duodenal mucosa. J Bone Mineral Res 1997; 12(Suppl, 1): S468(Abstract).
32. Graham DY. Effectiveness and tolerance of 'solid vs. liquid' potassium replacement therapy: Arrhythmias, myocardial infarction, and hypertension. In: Welton PK, Welton A, Gordon Walker W, eds. Potassium in Cardiovascular and Renal Medicine. New York: Marcel Dekker Inc., 1986: 415-50.
33. Graham DT, Smith JL, Bouvet AA. What happens to tablets and capsules in the stomach: Endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations. J Pharmaceutical Sci 1990; 79: 420-4.
34. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997; 42: 281-8.